Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Bayer Ag Ord (OP: BAYZF ) 32.74 +0.07 (+0.23%) Streaming Delayed Price Updated: 11:35 AM EDT, Oct 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Bayer Ag Ord < Previous 1 2 3 Next > Futures Rally Fizzles As Dollar, Yields And Oil Slump August 17, 2024 US equity futures erased earlier gains and were trading with modest losses as the dollar, oil, and yields all slumped entering the US session. Via Talk Markets Bayer Weedkiller Lawsuit Dismissed By Australian Judge: Insufficient Evidence Linking Roundup To Blood Cancer July 25, 2024 Australian judge dismisses class action lawsuit against Bayer for Roundup causing cancer. Ruling supports company's stance that product is safe. Via Benzinga Topics Lawsuit Exposures Financial Glyphosate Legal Judge Slashes Bayer's Massive $2B Roundup Verdict To $400M June 05, 2024 Pennsylvania judge cuts Bayer's $2.25 billion Roundup verdict to $400 million. Both Bayer and plaintiff plan appeals in the ongoing cancer litigation. Via Benzinga Exposures Glyphosate After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February May 24, 2024 Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications. Via Benzinga Topics Data Breach Exposures Information Security Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval May 17, 2024 Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe menopausal vasomotor symptoms compared to placebo. Via Benzinga Bayer's Monsanto Scores Legal Victory as $185M Verdict Overturned May 02, 2024 Bayer's Monsanto unit secures a significant legal victory as Washington state appeals court overturns $185 million verdict over chemical contamination. This highlights broader legal battles over PCBs... Via Benzinga Exposures Glyphosate Bayer's Third Menopausal Relief Drug Trial Meets Primary Goal, German Conglomerate Seeks FDA Approval For Elinzanetant March 19, 2024 Bayer's Phase 3 study OASIS 3 findings on elinzanetant, a promising non-hormonal treatment for menopausal hot flashes. Results show significant reduction in symptoms over 12 weeks, marking a potential... Via Benzinga Exposures Product Safety German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits March 14, 2024 Bayer contemplates Texas Two-Step bankruptcy to tackle Roundup lawsuits in the US amid mounting jury verdicts. Learn about the controversial tactic and its potential implications. Via Benzinga Topics Bankruptcy Lawsuit Exposures Financial Glyphosate Legal Bayer Holds Splitting Into Separate Units For Three Years, Focus Shifts On Tackling Challenges March 05, 2024 Bayer charts strategic course amid structural evaluation. CEO Bill Anderson addresses group's challenges, prioritizing performance and flexibility. The company's focus and fiscal outlook for 2024. Via Benzinga What's Going On With BridgeBio Pharma Stock On Monday? March 04, 2024 BridgeBio Pharma partners with Bayer on acoramidis for ATTR-CM in Europe. $310 million deal, FDA application accepted. Via Benzinga Exposures Product Safety Weedkiller Woes: Australian Court Nears Decision in Bayer's Roundup Trial January 30, 2024 Follow the landmark Australian Roundup lawsuit against Bayer. Closing arguments in class action alleging Roundup's link to cancer. Via Benzinga Topics Lawsuit Exposures Financial Glyphosate Legal Roundup Cancer Verdict: Woes Continue For Bayer As It Faces $2.2B Payout January 29, 2024 "Bayer's Monsanto ordered to pay $2.2 billion in Roundup cancer case. Explore the landmark verdict, compensatory losses, and punitive damages. Via Benzinga Exposures Glyphosate Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance January 11, 2024 Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the Via Benzinga Menopause Management: Bayer's Non-Hormonal Treatment Option Shows Efficacy In Trial January 08, 2024 Monday, Bayer AG (OTC: BAYRY (OTC: BAYZF) Via Benzinga Bayer Study On Parkinson's Disease Gene Therapy Succeeds In Early-Stage Trial January 04, 2024 Bayer completed an 18-month data collection in the Phase Ib trial for a gene therapy for treating patients with Parkinson's. Via Benzinga Legal Victory For Bayer: Roundup Lawsuit Ends Five-Trial Losing Streak December 26, 2023 In a significant turn of events, Bayer AG (OTC: BAYRY) (OTC: BAYZF) emerged victorious in a California lawsuit filed by Bruce Jones, who alleged that the use of Roundup caused his non-Hodgkin... Via Benzinga Topics Lawsuit Exposures Financial Glyphosate Legal ESG Stocks Take Center Stage As Damages From Climate-Related Events Rise Exponentially Within US December 19, 2023 With climate change becoming a mega market force, ESG investing is rising. The XVV is up 28% YTD. Agri-Tech stocks like Bayer AG, FMC Corporation, and Corteva Inc are providing climate resilience... Via Benzinga Topics Climate Change Exposures Climate Bayer Faces $3.5M Verdict in Fifth Consecutive Roundup Weedkiller Loss December 06, 2023 Bayer AG (OTC: BAYRY) (OTC: Via Benzinga Exposures Glyphosate Bayer Faces Growing Pressure Amid Roundup Lawsuits as Philadelphia Trial Nears Conclusion December 04, 2023 The spotlight is on a Philadelphia trial as Bayer AG (OTC: BAYRY) (OTC: BAYZF) grapples with mounting legal challenges surrounding its Roundup weedkiller, prompted by multi-billion dollar verdicts Via Benzinga Topics Lawsuit Exposures Financial Glyphosate Legal German Conglomerate Bayer Faces Investor Scrutiny Amid Unexpected Legal, Trial Setbacks November 24, 2023 Bayer AG (OTC: BAYRY) (OTC: BAYZF) reportedly held an investor call to address concerns after intense scrutiny from investors following a series of unforeseen setbacks, prompting questions about... Via Benzinga Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence November 20, 2023 Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF) Via Benzinga Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details November 20, 2023 Bayer AG (OTC: BAYRY) (OTC: BAYZF) Via Benzinga Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits November 17, 2023 The Delaware Supreme Court reportedly ruled in favor of Bayer AG (OTC: BAYRY) (OTC: BAYZF), stating that the company is not accountable for lawsuits associated with talc-based foot powder products... Via Benzinga Topics Lawsuit Exposures Financial Legal Bayer CEO Resists Full Tri-Split, German Conglomerate Cuts Management Jobs In The Face Of Q3 Loss November 08, 2023 Bayer AG (OTC: BAYRY) (OTC: BAYZF) CEO Bill Anderson announced Via Benzinga Legal Woes Mount for Bayer As Roundup Weed Killer-Related Cancer Cases Continue, Faces Third Trial Loss November 01, 2023 Bayer AG (OTC: BAYRY) (OTC: Via Benzinga Exposures Glyphosate From Years to Months: How AI is Shaping the Landscape of Clinical Trials September 22, 2023 Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These... Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories August 28, 2023 Reuters Via Benzinga German Pharma Firm Bayer's New Parkinson's Treatment Shows Promise: What the Phase 1 Trial Reveals August 28, 2023 Boston Scientific Corporation (NYSE: BSX) released 12-month results from the pivotal ADVENT trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a nonthermal treatment in which electric fields... Via Benzinga FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness August 21, 2023 The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME), Via Benzinga Exposures Product Safety AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer June 29, 2023 AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)... Via Benzinga < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.